Drugs / Abrilumab
Abrilumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01164904 | Jul 2010 → Jan 2013 | ulcerative colitis | Amgen | Terminated | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT01959165 | Nov 2013 → Aug 2015 | ulcerative colitis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01696396 | Dec 2012 → Dec 2014 | Crohn disease | Amgen | Completed | Missed primary |
| Phase 2 | NCT01694485 | Nov 2012 → Jul 2015 | ulcerative colitis | Amgen | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01290042 Comparator | Feb 2011 → Apr 2014 | Crohn disease, ulcerative colitis | Amgen | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abrilumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01694485 ↗ |
| Known as | AMG 181 | “Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.” NCT01164904 ↗3“Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease” NCT01696396 ↗ |
| Known as | MEDI7183 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01959165 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3137351 ↗ |
| Route | Intravenous | “Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.” NCT01164904 ↗ |
| Route | Subcutaneous | “Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.” NCT01164904 ↗ |